Description:
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing
dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor
(CPI) pembrolizumab. The Phase 1b study will determine the optimal dose and schedule of
ilixadencel. Patients in the Phase 2 part of the study will be randomly assigned to receive
either ilixadencel (at the dose determined in Phase 1b) combined with the CPI, or only the
CPI.
Note: Recruitment to Phase 1b of the study has been completed.
Title
- Brief Title: A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
- Official Title: A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy
Clinical Trial IDs
- ORG STUDY ID:
IM-202
- NCT ID:
NCT03735290
Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Non-small Cell Lung Cancer
Interventions
Drug | Synonyms | Arms |
---|
ilixadencel | | Phase 1b: Cohort 1, ilixadencel + pembrolizumab |
Pembrolizumab | | Phase 1b: Cohort 1, ilixadencel + pembrolizumab |
Purpose
Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing
dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor
(CPI) pembrolizumab. The Phase 1b study will determine the optimal dose and schedule of
ilixadencel. Patients in the Phase 2 part of the study will be randomly assigned to receive
either ilixadencel (at the dose determined in Phase 1b) combined with the CPI, or only the
CPI.
Note: Recruitment to Phase 1b of the study has been completed.
Detailed Description
Despite improvements achieved with the use of CPIs, 50-80% of cancer patients do not respond
to this therapy. There is growing evidence that combining CPIs with other forms of
immunotherapy has the potential to improve the desired effects of both CPIs and
immunotherapies. This study looks at the safety and effectiveness of the immunotherapy
ilixadencel when used in combination with a CPI. A Dose-escalation Committee (DEC) will
monitor the study for any significant safety issues during Phase 1b.
Note: Recruitment to Phase 1b of the study has been completed.
Trial Arms
Name | Type | Description | Interventions |
---|
Phase 1b: Cohort 1, ilixadencel + pembrolizumab | Experimental | 3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab I.V. q3w | |
Phase 1b: Cohort 2, ilixadencel + pembrolizumab | Experimental | 10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w | |
Phase 1b: Cohort 3, ilixadencel + pembrolizumab | Experimental | 10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w | |
Phase 1b: Cohort 4, ilixadencel + pembrolizumab | Experimental | Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w | |
Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ | Experimental | Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications. | |
Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ | Active Comparator | Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications. | |
Eligibility Criteria
Inclusion Criteria:
- Must provide written informed consent.
- Must have histologically confirmed and specific (Human Papilloma Virus) HPV-positive
or HPV-negative squamous cell carcinoma of the head and neck (SCCHN), non-small-cell
lung cancer (NSCLC) or gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Patients with other tumor types who are candidates for pembrolizumab therapy
(according to the FDA-approved prescribing information at the time of inclusion) can
also be enrolled in Phase 1b. Tumor histology and most recent pathology report must be
in subject's medical record. Tumor samples and/or biopsies will not be collected as
part of this study.
- Eligible for pembrolizumab treatment per country-specific label and per physician's
decision.
- ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.
- Adequate organ function.
- Women of childbearing potential must follow contraceptive requirements; must have a
negative pregnancy blood test at screening, and a negative blood or urine pregnancy
test within 24 hours before each dose of ilixadencel; and must not be breastfeeding.
- Male subjects must agree to use condoms from screening until 90 days after the last
dose of ilixadencel, or must have a female partner using a highly effective method of
contraception as described above.
Exclusion Criteria:
- Prior history of invasive malignancy, unless complete remission has been achieved for
at least 3 years and no additional therapy is required except for hormonal therapy or
bisphosphonates.
- Active or previously untreated brain and/or leptomeningeal metastasis.
- Active autoimmune disease, pneumonitis or interstitial lung disease.
- Certain heart conditions including, but not limited to: Congestive heart failure;
uncontrolled hypertension; unstable angina pectoris; pericarditis; myocarditis;
mycardial infarction 6 months prior to study.
- Systemic immunosuppression except for replacement therapy.
- Life expectancy of less than 3 months.
- Any prior treatment with ilixadencel or prior treatment with anticancer agents (except
pembrolizumab or other CPI for subjects in Phase 1b) within 4 weeks of starting study
medication.
- Major surgery or significant traumatic injury within 4 weeks before study start.
- Known infection with human immunodeficiency virus (HIV).
- Active tuberculosis; active infection requiring anti-infective therapy (hepatitis with
a negative viral load on maintenance will not be excluded).
Other protocol-defined inclusion/exclusion criteria could apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Frequency of adverse events (AEs) (Phase 1b) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Number of adverse events |
Secondary Outcome Measures
Measure: | Antitumor Objective Response Rate (ORR) RECIST 1.1 (Phase 1b and Phase 2) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, investigator and centrally assessed using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1 |
Measure: | Antitumor Objective Response Rate (ORR) iRECIST (Phase 1b and Phase 2) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, investigator assessed using iRECIST (Immune Response Evaluation Criteria in Solid Tumors) |
Measure: | Clinical Benefit Rate (Phase 1b and Phase 2) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Rate of complete and partial response and stable disease by investigator and centrally assessed RECIST (Response Evaluation Criteria in Solid Tumors) v1.1 |
Measure: | Duration of response (Phase 1b and Phase 2) |
Time Frame: | Up to 24 months after Cycle 1 Day 1 |
Safety Issue: | |
Description: | Measured in weeks. Assessed using RECIST v1.1 and iRECIST |
Measure: | Time to Progression (TTP) (Phase 1b and Phase 2) |
Time Frame: | Up to 24 months after Cycle 1 Day 1 |
Safety Issue: | |
Description: | Measured in weeks. Assessed using RECIST v1.1 and iRECIST |
Measure: | Progression-free Survival (PFS) (Phase 1b and Phase 2) |
Time Frame: | Up to 24 months after Cycle 1 Day 1 |
Safety Issue: | |
Description: | Measured in weeks. Centrally assessed using RECIST v1.1 |
Measure: | Overall Survival (OS) (Phase 1b and Phase 2) |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | Measured in months |
Measure: | Frequency of adverse events (AEs) (Phase 2) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Number of adverse events |
Measure: | Severity of adverse events (AEs) (Phase 2) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
Measure: | Number of Dose Limiting Toxicities (DLTs) (Phase 2) |
Time Frame: | Up to week 27 |
Safety Issue: | |
Description: | Dose Limiting Toxicities measured using CTCAE v5.0 and protocol DLT definition. |
Measure: | Number of subjects with clinically significant laboratory test abnormalities (Phase 2) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
Measure: | Number of subjects with vital sign abnormalities (Phase 2) |
Time Frame: | Up to Week 27 |
Safety Issue: | |
Description: | Vital signs grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Immunicum AB |
Trial Keywords
- immunotherapy
- ilixadencel
- checkpoint inhibitor
- allogeneic
- somatic cell therapy
- dendritic cell
- intratumoral
- in situ
Last Updated
May 7, 2021